Lexaria Bioscience: Lexaria Bioscience Corp. (NASDAQ:LEXX) to Post FY2024 Earnings of ($0.60) Per Share, Zacks Small Cap Forecasts

Lexaria Bioscience Corp. ( NASDAQ:LEXX - Free Report ) - Investment analysts at Zacks Small Cap increased their FY2024 earnings per share estimates for Lexaria Bioscience in a report released on Thursday, November 30th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.60) per share for the year, up from their previous estimate of ($0.66). The consensus estimate for Lexaria Bioscience's current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience's FY2025 earnings at ($0.51) EPS. Lexaria Bioscience Price Performance Shares of LEXX stock opened at $1.52 on Monday. Lexaria Bioscience has a one year low of $0.65 and a one year high of $3.60. The business's 50 day simple moving average is $1.24 and its 200 day simple moving average is $0.99. The stock has a market capitalization of $15.63 million, a PE ratio of -1.50 and a beta of 0.49. Hedge Funds Weigh In On Lexaria Bioscience About Lexaria Bioscience ( Get Free Report ) Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. See Also Five stocks we like better than Lexaria Bioscience What Does Downgrade Mean in Investing? Are penny stocks worth it? Should you invest in penny stocks? How to Invest in Energy Why do tech stocks go down when interest rates rise? How to Invest in Virtual Reality Snowflake's bullish tailwind is turning into a gale-force wind Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter .